Insurance Denied Migraine Treatment? Step-by-Step Appeal Guide

Migraine is a disabling neurological disease affecting approximately 39 million Americans, yet insurance denials for migraine treatment — particularly CGRP antagonist medications, Botox injections for chronic migraine, and newer preventive therapies — are remarkably common. Insurers apply step therapy requirements and outdated criteria that contradict American Headache Society (AHS) and American Academy of Neurology (AAN) guidelines. These denials are reversible with the right clinical evidence and legal arguments.

Why Insurers Deny Migraine Treatment

Migraine treatment denials follow predictable patterns that your appeal must address directly.

Step therapy for CGRP inhibitors. Calcitonin gene-related peptide (CGRP) antagonists — including erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) — are frequently denied until the patient has tried and failed multiple older preventive medications including topiramate, valproate, propranolol, and amitriptyline. While step therapy can be a legitimate insurer requirement, many plans demand failure of medications that are contraindicated or have already been tried in your clinical history.

Botox for chronic migraine denied. OnabotulinumtoxinA (Botox) is FDA-approved for chronic migraine (15 or more headache days per month, of which 8 or more are migraine), but insurers routinely deny it by challenging the frequency documentation, claiming non-compliance with prior preventive trials, or applying more restrictive criteria than the FDA label requires.

CGRP antagonists classified as "not medically necessary." Some insurers deny CGRP inhibitors by arguing that the patient has not adequately documented migraine frequency, severity, or disability using standardized tools such as the MIDAS or HIT-6 questionnaire. If your records do not include this documentation, the denial may resolve with updated standardized assessments.

"Experimental" classification of gepants and ditans. Newer acute migraine treatments including rimegepant (Nurtec ODT), ubrogepant (Ubrelvy), and lasmiditan (Reyvow) receive FDA approval but may be classified as experimental by insurers applying outdated clinical criteria or not yet updated formularies. The AHS First Choice designation and FDA prescribing information are your rebuttal evidence.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denied or expired. Virtually all CGRP inhibitors and Botox require prior authorization. Denials occur when authorization was not obtained, expired, or was obtained under a different clinical indication than what was billed.

How to Appeal

Step 1: Identify the Specific Denial Reason and Criteria

Request the insurer's clinical policy bulletin for migraine treatment. Compare their criteria to the current AHS consensus statement and AAN practice guidelines for migraine treatment, which are updated regularly and support CGRP inhibitors and Botox as first-line options for appropriate patients.

Step 2: Document Your Migraine History Comprehensively

Compile a headache diary showing frequency, severity, and disability over at least 3 months. Complete the MIDAS (Migraine Disability Assessment) and HIT-6 (Headache Impact Test) questionnaires with your neurologist. Document every prior preventive treatment tried, the duration of each trial, the doses used, and why each was discontinued (side effects, contraindication, or inadequate response). This documentation directly addresses the most common denial criteria.

Step 3: Get a Detailed Letter from Your Neurologist

Your treating neurologist or headache specialist should write a letter documenting your migraine diagnosis using IHS criteria, frequency and severity data, prior treatment history and outcomes, why the denied treatment is medically appropriate for your profile, and citations to AHS guidelines and FDA approval documentation. If step therapy requirements were met, the letter should explicitly state this and attach the relevant treatment records.

Step 4: Challenge Step Therapy Requirements

If the denial is based on failure to exhaust prior therapies, and those therapies are contraindicated for you (e.g., valproate in pregnancy, propranolol in asthma, topiramate causing cognitive impairment), document the contraindication explicitly. Many states have step therapy override laws requiring insurers to waive step therapy requirements when the required first-step drug is contraindicated, previously ineffective, or otherwise inappropriate. The Step Therapy Access Act provisions in numerous states also provide a framework for challenging unreasonable step therapy requirements.

Step 5: File the Internal Appeal

Submit your appeal via certified mail with the neurologist's letter, AHS guidelines, headache diary, MIDAS and HIT-6 scores, prior treatment records, and your point-by-point response to the insurer's clinical criteria. Under ACA regulations (45 CFR § 147.136), insurers cannot apply clinical criteria that are more restrictive than recognized evidence-based guidelines. Request a response within 30 days.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review

If the internal appeal is denied, request external review by an independent neurologist. For ERISA plans, external review rights are established under 29 U.S.C. § 1133. For ACA plans, under 42 U.S.C. § 300gg-19. External reviewers with headache medicine expertise frequently overturn denials for established migraine therapies.

What to Include in Your Appeal

• Current AHS consensus statement and AAN practice guidelines for migraine prevention supporting the denied treatment
• Neurologist's letter with IHS diagnosis criteria, migraine frequency data, prior treatment history, and medical justification
• Headache diary and standardized disability scores (MIDAS, HIT-6)
• Documentation of prior treatment attempts with outcomes, including contraindications to step therapy requirements
• FDA approval documentation and indication for the denied drug

Fight Back With ClaimBack

Migraine treatment denials frequently rely on step therapy requirements that can be overridden and criteria that contradict AHS guidelines and FDA approvals. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal